JP2019528694A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528694A5
JP2019528694A5 JP2019510931A JP2019510931A JP2019528694A5 JP 2019528694 A5 JP2019528694 A5 JP 2019528694A5 JP 2019510931 A JP2019510931 A JP 2019510931A JP 2019510931 A JP2019510931 A JP 2019510931A JP 2019528694 A5 JP2019528694 A5 JP 2019528694A5
Authority
JP
Japan
Prior art keywords
bispecific antibody
scfv
seq
domain
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528694A (ja
JP7174691B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/071104 external-priority patent/WO2018037000A1/en
Publication of JP2019528694A publication Critical patent/JP2019528694A/ja
Publication of JP2019528694A5 publication Critical patent/JP2019528694A5/ja
Application granted granted Critical
Publication of JP7174691B2 publication Critical patent/JP7174691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510931A 2016-08-23 2017-08-22 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用 Active JP7174691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378388P 2016-08-23 2016-08-23
US62/378,388 2016-08-23
PCT/EP2017/071104 WO2018037000A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a and anti-ang2 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2019528694A JP2019528694A (ja) 2019-10-17
JP2019528694A5 true JP2019528694A5 (OSRAM) 2020-10-01
JP7174691B2 JP7174691B2 (ja) 2022-11-17

Family

ID=59714013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510931A Active JP7174691B2 (ja) 2016-08-23 2017-08-22 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用

Country Status (10)

Country Link
US (2) US10836819B2 (OSRAM)
EP (1) EP3504237A1 (OSRAM)
JP (1) JP7174691B2 (OSRAM)
KR (1) KR102543878B1 (OSRAM)
CN (1) CN109863171B (OSRAM)
AU (1) AU2017315075B2 (OSRAM)
CA (1) CA3034574A1 (OSRAM)
IL (1) IL264962B2 (OSRAM)
MA (1) MA46036A (OSRAM)
WO (1) WO2018037000A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CA3190173A1 (en) * 2020-06-22 2021-12-30 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and use thereof
MX2023002496A (es) 2020-09-04 2023-03-09 Hoffmann La Roche Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.
EP4313148A4 (en) * 2021-03-30 2025-02-19 Abpro Corporation METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
US11883030B2 (en) 2022-04-29 2024-01-30 inQB8 Medical Technologies, LLC Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
EP4514271A1 (en) 2022-04-29 2025-03-05 Inqb8 Medical Technologies, LLC Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
WO2024085606A1 (ko) * 2022-10-20 2024-04-25 (주)니오테스바이오 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
ATE363291T1 (de) 2000-06-23 2007-06-15 Bayer Schering Pharma Ag Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
KR101017301B1 (ko) 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
EP3168234A1 (en) * 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
DK1974040T3 (da) 2006-01-17 2012-12-17 Synthon Biopharmaceuticals Bv Sammensætninger og fremgangsmåder til humanisering og optimering af N-glycanet i planter.
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2009055343A2 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
JP5596559B2 (ja) 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CN102250248A (zh) * 2011-06-15 2011-11-23 常州亚当生物技术有限公司 抗vegf/ang2双特异性抗体及其应用
AU2012336069A1 (en) * 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
MX361337B (es) * 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
KR20150063847A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-A/항 Ang2 이중 특이 항체
CA2946906A1 (en) * 2014-05-07 2015-11-12 Medimmune, Llc Methods of using anti-ang2 antibodies
CN107074941A (zh) * 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2

Similar Documents

Publication Publication Date Title
JP2019528694A5 (OSRAM)
JP2015535828A5 (OSRAM)
JP2017505125A5 (OSRAM)
EP4286415A3 (en) Humanized antigen-binding domains against cd19 and methods of use
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
JP2009539348A5 (OSRAM)
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
JP2013506428A5 (OSRAM)
WO2011051327A3 (en) Small antibody-like single chain proteins
JP2017114866A5 (OSRAM)
JP2020514277A5 (OSRAM)
JP2020504101A5 (OSRAM)
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
JP2015504421A5 (OSRAM)
JP2014526898A5 (OSRAM)
JP2021501744A5 (OSRAM)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2020524000A5 (OSRAM)
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NO20066052L (no) Anti-CD3 antistoffer og fremgangsmater for anvendelse derav
JP2016514463A5 (OSRAM)
JP2013538057A5 (OSRAM)
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
JP2013198490A5 (OSRAM)